SCHEMBL3484594

SCHEMBL3484594

COC(=O)C(C)(C)CCCOc1ccccc1-c1ccc(C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
MAPK1 P28482 1/20 0.48
KDM4E B2RXH2 10/20 0.47
ALDH1A1 P00352 5/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
PPARA Q07869 2/20 0.45
TTR P02766 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C8 P10632 1/20 0.45
CHRM1 P11229 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
ADRA1A P35348 1/20 0.45
PPARG P37231 1/20 0.45
HTR2B P41595 1/20 0.45
SLCO1B3 Q9NPD5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3484528 0.95 LTB4R (0.48) LMNAL3MBTL1TDP1MAPK1KDM4E
SCHEMBL4033345 0.87 PPARA (0.60) LMNAL3MBTL1TDP1MAPK1KDM4E
SCHEMBL3484380 0.87 KDM4E (0.45) L3MBTL1KDM4EALDH1A1GAAHTT
SCHEMBL4035625 0.82 LTB4R (0.61) LMNAL3MBTL1TDP1MAPK1KDM4E
SCHEMBL3484078 0.82 KDM4E (0.45) L3MBTL1KDM4EALDH1A1GAAHTT
SCHEMBL3485000 0.80 PPARA (0.58) L3MBTL1TDP1MAPK1SMN1; SMN2PPARA
SCHEMBL11091256 0.80 PPARA (0.46) LMNAL3MBTL1TDP1GAASMN1; SMN2
SCHEMBL10683854 0.78 PPARA (0.62) L3MBTL1TDP1HTTSMN1; SMN2PPARA
SCHEMBL12958327 0.77 SYK (0.52) LMNAL3MBTL1TDP1MAPK1KDM4E
SCHEMBL3483931 0.77 FFAR4 (0.53) TDP1SMN1; SMN2PPARATTRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 LMNA 3094/4885L3MBTL1 4843/4885TDP1 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.